As Biotechnology businesses, PDL BioPharma Inc. (NASDAQ:PDLI) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDL BioPharma Inc. 110.52M 4.31 68.86M -0.42 0.00 Citius Pharmaceuticals Inc. N/A 0.00 13.17M -1.06 0.00 Demonstrates PDL BioPharma Inc. and Citius Pharmaceuticals Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 shows the net margins, return on equity and return on assets of the two firms. Net Margins Return on Equity Return on Assets Citius Pharmaceuticals Inc. 0.00% -54.2% -48.3% Risk & Volatility
A 0.65 beta indicates that PDL BioPharma Inc. is 35.00% less volatile compared to Standard & Poor’s 500. Competitively, Citius Pharmaceuticals Inc. is 19.00% more volatile than Standard & Poor’s 500, because of the 1.19 beta.
PDL BioPharma Inc.’s Current Ratio is 10.9 while its Quick Ratio is 10.6. On the competitive side is, Citius Pharmaceuticals Inc. which has a 1.8 Current Ratio and a 1.8 Quick Ratio. PDL BioPharma Inc. is better positioned to pay off short and long-term obligations compared to Citius Pharmaceuticals Inc.
Insider & Institutional Ownership
Roughly 83.6% of PDL BioPharma Inc. shares are held by institutional investors while 5% of Citius Pharmaceuticals Inc. are owned by institutional investors. Insiders held 0.8% of PDL BioPharma Inc. shares. Comparatively, 44.4% are Citius Pharmaceuticals Inc.’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) PDL BioPharma Inc. 2.44% 18.87% 22.33% 60.85% 55.56% 30.34% Citius Pharmaceuticals Inc. 6.03% 28.13% 3.36% -16.33% -64.76% 18.27% For the past year PDL BioPharma Inc. has stronger performance than Citius Pharmaceuticals Inc.
PDL BioPharma Inc. beats on 7 of the 9 factors Citius Pharmaceuticals Inc.
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Click here to view original web page at Reviewing PDL BioPharma Inc. (PDLI)’s and Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s results